Nissan Chemical Corporation
Stock Price Chart
2026/11/20 13:29 UpdatedPrice Trend
2026/11/20 13:29 UpdatedPrice & Trading Details
2026/11/20 13:29 UpdatedPRICE
TRADING
Analyst Recommendations 9 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/06 | ¥110.72 | ¥125.74 | +13.6% |
| 2026/05/15 | ¥104.00 | ¥109.16 | +5.0% |
| 2026/02/09 | ¥73.47 | ¥90.65 | +23.4% |
| 2025/11/10 | ¥70.35 | ¥66.25 | -5.8% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.8M | -0.02% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.2M | +2.04% | |
|
Fidelity Investment Trust-Fidelity Diversified International Fund
|
1.0M | +7.50% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
939.5K | +1.23% | |
|
Fidelity Investment TRT-Fidelity SAI Intl SMA Completion Fd.
|
876.7K | 0.00% | |
|
Fidelity Investment Trust-Fidelity Diversified International K6 Fund
|
554.3K | +4.29% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
20 | +1.00% |
Dividend History 2Years Growth
Updated 2026/11/22| Year | Dividend | Change |
|---|---|---|
| 2027 In Progress | ¥78 | - |
| 2026 | ¥202 | +16.1% |
| 2025 | ¥174 | +6.1% |
| 2024 | ¥164 | 0.0% |
| 2023 | ¥164 | - |
Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥207,972M | ¥228,065M | ¥226,705M | ¥251,365M |
| Gross Profit | ¥101,089M | ¥106,803M | ¥104,774M | ¥116,541M |
| Operating Income | ¥50,960M | ¥52,284M | ¥48,202M | ¥56,833M |
| Pretax Income | ¥54,233M | ¥56,857M | ¥52,311M | ¥60,124M |
| Net Income | ¥38,776M | ¥41,087M | ¥38,033M | ¥43,043M |
| EPS | ¥271.88 | ¥291.36 | ¥272.82 | ¥313.26 |
| Operating Margin | 24.50% | 22.93% | 21.26% | 22.61% |
| Balance Sheet | ||||
| Total Assets | ¥279,687M | ¥298,715M | ¥323,458M | ¥330,763M |
| Total Equity | ¥205,910M | ¥218,418M | ¥227,519M | ¥233,290M |
| Total Liabilities | ¥73,777M | ¥80,297M | ¥95,939M | ¥97,473M |
| Cash | ¥34,658M | ¥29,647M | ¥22,738M | ¥27,454M |
| Interest-bearing Debt | ¥22,715M | ¥27,289M | ¥40,980M | ¥40,474M |
| Equity Ratio | 73.62% | 73.12% | 70.34% | 70.53% |
| D/E Ratio | 0.11 | 0.12 | 0.18 | 0.17 |
| Cash Flow | ||||
| Operating CF | ¥41,949M | ¥35,226M | ¥33,701M | ¥59,178M |
| Investing CF | -¥12,395M | -¥19,643M | -¥18,741M | -¥17,612M |
| Financing CF | -¥27,868M | -¥25,030M | -¥22,101M | -¥35,650M |
| Free CF | ¥29,097M | ¥15,053M | ¥12,703M | ¥40,810M |
| Efficiency | ||||
| ROE | 18.83% | 18.81% | 16.72% | 18.45% |
| ROA | 13.86% | 13.75% | 11.76% | 13.01% |
Latest IR Information
-
Fiscal Year Ending March 2027 Q2 Earnings Presentation Materials
Nissan Chemical Corporation announced its consolidated results for the first half of fiscal 2026. Revenue rose +12% year-over-year, operating income +16%, and net income +14%, reaching record highs. The company revised its full-year forecast upward, expecting growth across segments including...
Read more -
FY2026 First Half Earnings Presentation Materials
For the first half of FY2026, net sales were revised upward from 130.1 billion yen to 145.6 billion yen, operating income increased from 29.6 billion yen to 34.2 billion yen, and net income rose to 26.0 billion yen. Interim dividend...
Read more -
Notice Regarding Differences Between Consolidated Earnings Forecasts and Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027
Differences arose between the consolidated earnings forecasts and actual results for the second quarter of the fiscal year ending March 2027. Net sales were revised upward from 131,500 million yen to 145,584 million yen (+14,084 million yen), operating income was...
Read more -
Notice Regarding Revision of Earnings Guidance, Distribution of Surplus (Interim Dividend) and Revision of Annual Dividend Forecast
Revised the consolidated full-year earnings guidance for the fiscal year ending March 2027. Sales are expected to be up 7.4% from the previous forecast, operating income +8.4%, and net income attributable to owners of parent +3.5%. Increases are expected across...
Read more -
Nissan Chemical Corporation (4021) Financial Summary for the Second Quarter (Interim) of the Fiscal Year Ending March 2027
For the second quarter of the fiscal year ending March 2027, consolidated revenue was 145,584 million yen, up 11.9% year-over-year. Operating income was 34,192 million yen, up 16.4% year-over-year, and interim net income attributable to owners of parent was 26,028...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥9,244
Rating Score: 1.89 (Based on 9 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Nissan Chemical Corporation engages in the chemicals, performance materials, agricultural chemicals, and healthcare businesses in Japan and internationally. It provides high purity and custom chemicals; AdBlue, an urea solution; ammonia, sulfuric, and nitric acid, as well as concrete and construction-related products; TEPIC, an epoxy compound; Melamine Cyanurate, a salt of melamine and iso cyanuric acid; TEPIC-VL, a liquid epoxy compound; Nissan Reishi, a health food; phenylphosphonic acid; HI-LITE, a chlorinated isocyanulate; FINEOXOCOL, a saturated fatty alcohol and acid; Melamine particles, a spherical fine particles; STARFINE, a Triazine based adhesion; melamine polyphosphate; and NFG, a highly functional additive. The company also offers performance materials comprising display, semiconductor, and inorganic materials; agricultural chemicals, such as herbicides, insecticides, fungicides, etc. for use on agricultural land, as well as in golf courses and parks; and drug substances for antiparasite drugs for animals. In addition, it provides pharmaceutical products, such as LIVALO, a drug for treating hypercholesterolemia; LANDEL and FINTE, a long-acting calcium channel blocker; and develops NTC-801, a pharmacological for treatment of arrhythmia. Further, it develops life science, information and communication, and energy materials. The company was formerly known as Nissan Chemical Industries, Ltd. and changed its name to Nissan Chemical Corporation in July 2018. Nissan Chemical Corporation was founded in 1887 and is headquartered in Chuo, Japan.